Email this page
Print this page
Special Focus: Patenting Antibodies
Guardians at the gate: Patent protection for therapeutic monoclonal antibodies (Part 1)
Kevin W. McCabe
Volume 1, Issue 4July/August 2009
Pages 382 - 384
Purchase article for $19
Subscribe to this journal
» Log in
Patents provide one of the few protections companies can avail themselves of to help protect their therapeutic monoclonal antibody products. Just as the therapeutic monoclonal antibody field is constantly evolving, so too is the legal environment surrounding these inventions. In a series of articles, the general state of the law surrounding therapeutic antibodies will be explained, and important challenges to this technology area will be discussed. Much is at stake when companies market therapeutic monoclonal antibodies; therefore, a firm understanding of this important form of protection is critically important for anyone developing such products.
Authors
- Kevin W. McCabe Corresponding author: kmccabe@skgf.com
- Sterne, Kessler, Goldstein & Fox, P.L.L.C.
Purchase article for $19
Subscribe to this journal
» Log in
Advertisements
